Hostname: page-component-77c89778f8-n9wrp Total loading time: 0 Render date: 2024-07-16T13:46:00.066Z Has data issue: false hasContentIssue false

Large-scale Production of Anti-lymphocytic Antibody

Published online by Cambridge University Press:  11 June 2012

D. A. Long
Affiliation:
The Wellcome Research Laboratories, Beckenham, Kent
D. C. Edwards
Affiliation:
The Wellcome Research Laboratories, Beckenham, Kent
A. W. Phillips
Affiliation:
The Wellcome Research Laboratories, Beckenham, Kent
A. J. Woiwod
Affiliation:
The Wellcome Research Laboratories, Beckenham, Kent
Get access

Extract

The Wellcome Foundation is part of the M.R.C. Working Party on A.L.S. and the main role of the Foundation, as agreed with the Working Party as a whole, is to produce A.L.S. on a large scale for use in man.

In Great Britain, the use of any new therapeutic agent is controlled by authority, in this case the Dunlop Committee. Before this committee could be approached for a licence to market such a product, it would be necessary for the pharmaceutical company concerned to have established conditions for large-scale production.

Type
Research Article
Copyright
Copyright © Royal Society of Edinburgh 1969

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References to Literature

Field, E. J., and Cook, D. B. G., 1969. Br. Med.J., 1, 227.CrossRefGoogle Scholar
Starzl, T. E., Marchioro, T. L., Porter, K. A., Iwasaki, Y. and Cerilli, G. J., 1967. Surgery Gynec. Obstet., 124, 301318.Google Scholar
Thomson, A. E. R., Bull, J. M. and Robinson, M. A., 1966. Br.J. Haemat., 12, 433.CrossRefGoogle Scholar
Wilson, J. D. and Grimes, A. J., 1968. Nature, Lond., 218, 178.CrossRefGoogle Scholar